Incidence of hypertension among persons living with HIV in China: a multicenter cohort study by Hongwei Fan, Fuping Guo, Evelyn Hsieh, Wei-Ti Chen, Wei Lv, Yang Han, Jing Xie, Yanling Li, Xiaojing Song, Taisheng Li

“…In the Cox regression analysis, incidence of hypertension was positively associated with body mass index [adjusted hazard ratio (aHR) 1.07 (1.01,1.13), p = 0.02] and recent viral load (aHR 1.28, 95% CI:1.08–1.51, p < 0.01), and negatively associated with recent CD4+/CD8+ ratio (aHR 0.14, 95% CI:0.06–0.31, p < 0.001), zidovudine exposure (aHR 0.15, 95% CI: 0.10–0.24, p < 0.001) and tenofovir disoproxil fumarate exposure (aHR 0.13, 95% CI: 0.08–0.21, p < 0.001). …”
Get full text

Caracterização clínico-epidemiológica de mulheres que receberam a profilaxia pós-exposição ao HIV em um hospital público de Porto Alegre, Rio Grande do Sul by Pamela Pereira Fagundes, Kátia Gonçalves dos Santos, Cátia Bauer Maggi

“…O esquema terapêutico utilizado com maior frequência foi a combinação com atazanavir, ritonavir e tenofovir associado à lamivudina. No primeiro atendimento, 8,0% das pacientes demonstraram resultados reagentes para o teste treponêmico de sífilis. …”
Get full text

Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM) by Florian Liégeois, Sylvie Boyer, Sabrina Eymard-Duvernay, Patrizia Carrieri, Charles Kouanfack, Jenny Domyeum, Gwenaëlle Maradan, Jacques Ducos, Eitel Mpoudi-Ngolé, Bruno Spire, Eric Delaporte, Christopher Kuaban, Laurent Vidal, Christian Laurent, for the EVOLCAM study group

“…Of 159 HBsAg-positive patients at the time of the study (9.3%), only 97 (61.0%) received Tenofovir + Lamivudine (or Emtricitabine). Of 157 coinfected patients, 114 (72.6%) had a HBV viral load < 10 IU/mL. …”
Get full text

Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China by Min Li, PhD, Lianhui Zhao, MD, Jialing Zhou, MSc, Yameng Sun, MD, Xiaoning Wu, MD, Xiaojuan Ou, MD, Hong You, MD, Yuanyuan Kong, PhD, Jidong Jia, MD

“…By 2018, entecavir (65•07%) and tenofovir (12•98%) had become the predominantly prescribed antiviral agents. …”
Get full text

Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy – Malawi option B+ by Maganizo B. Chagomerana, Bryna J. Harrington, Bethany L. DiPrete, Shaphil Wallie, Madalitso Maliwichi, Austin Wesevich, Jacob N. Phulusa, Wiza Kumwenda, Allan Jumbe, Mina C. Hosseinipour

“…Methods We conducted a prospective cohort study of pregnant women newly diagnosed with HIV who started tenofovir disoproxil fumarate/emtricitabine/efavirenz (TDF/3TC/EFV) for the first time at Bwaila Hospital in Lilongwe, Malawi between May 2015 and June 2016. …”
Get full text

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta by Lisa Sandmann, Cihan Yurdaydin, Katja Deterding, Benjamin Heidrich, Svenja Hardtke, Patrick Lehmann, Birgit Bremer, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer, Benjamin Maasoumy, HIDIT‐II Study Group

“…Patients were treated for 96 weeks with peg‐IFNα and either tenofovir or placebo. Ninety‐nine patients with HDV‐RNA results 24 weeks after end of treatment (FU24) were included in this analysis, of whom 32 patients (32.3%) had undetectable HDV RNA at FU24. …”
Get full text

HBcAb Positivity as a Risk Factor for Missing HIV RNA Undetectability after the 3TC+DTG Switch by Vincenzo Malagnino, Tiziana Mulas, Elisabetta Teti, Monica Basso, Mario Giobbia, Nicholas Geremia, Giuliana Battagin, Yasmine Abi Aad, Jean-Paul Vincensini, Marco Iannetta, Saverio Giuseppe Parisi, Loredana Sarmati, Karine Lacombe

“…This condition is not a contraindication for switching to two-drug (2DR) antiretroviral therapy; however, the removal of tenofovir may contribute to poor control of HBV replication. …”
Get full text

SIMPLIFICAÇÃO DA TARV HIV PARA TERAPIA DUPLA OU MONOTERAPIA: DEZ ANOS DE EFETIVIDADE DE UMA COORTE BRASILEIRA by Alexandre Naime Barbosa, Stephanie Valentini Ferreira Proença, Juliana Olsen Rodrigues, Vânia Vieira de Melo Fagundes Vidal, Lenice Do Rosário de Souza

“…Razões para a indicação de Simplificação: Toxicidade Óssea associada ao Tenofovir (49%), Toxicidade Renal pelo TDF (28%), Outros Motivos (Descontinuação da Didanosina, Toxicidade pela Zidivudina ou Efavirenz entre outros) (23%). …”
Get full text

Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-labe... by Jing Xiao, Jiang Xiao, Ying Liu, Bei Li, Leidan Zhang, Junyan Han, Hongxin Zhao

“…Methods: Virologically suppressed people living with HIV with a regimen composed of one-tablet tenofovir (TDF), one-tablet lamivudine (3TC), and one-tablet EFV (600 mg) were randomized to continue original regimen or switch to two-tablet EFV (200 mg). …”
Get full text

Association of HBsAg levels with differential gene expression in NK, CD8 T, and memory B cells in treated patients with chronic HBV by Boris J.B. Beudeker, Zgjim Osmani, Gertine W. van Oord, Zwier M.A. Groothuismink, Robert J. de Knegt, Remco M. Hoogenboezem, Eric M.J. Bindels, Harmen J.G. van de Werken, Andre Boonstra

“…Methods: An optimized 10x Genomics single-cell RNA sequencing workflow was applied to blood samples and liver fine-needle aspirates from 18 patients undergoing tenofovir/entecavir (NUC) treatment for chronic HBV infection. …”
Get full text

Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). by Jeanne Sibiude, Laurent Mandelbrot, Stéphane Blanche, Jérôme Le Chenadec, Naima Boullag-Bonnet, Albert Faye, Catherine Dollfus, Roland Tubiana, Damien Bonnet, Nathalie Lelong, Babak Khoshnood, Josiane Warszawski

“…No association was found between birth defects and lopinavir or ritonavir with a power >85% for an odds ratio of 1.5, nor for nevirapine, tenofovir, stavudine, or abacavir with a power >70%. …”
Get full text

Risk factors and longitudinal changes of dyslipidemia among Chinese people living with HIV receiving antiretroviral therapy by Xiuxia Li, Xiaojing Song, Yang Han, Zhifeng Qiu, Wei Cao, Taisheng Li

“…The regimens including efavirenz (EFV) and tenofovir (TDF) showed better lipid profiles. Longitudinal analysis revealed that both the level and the percentage of abnormal TG and HDL-C occurred drastic change in the first 6 months after ART initiation (from 4.07 to 4.41, from 1.11 to 1.28mmol/L, from 26.39 to 31.1% and from 44.94 to 29.5%, respectively). …”
Get full text

Evolution of myocardial oedema and fibrosis in HIV infected persons after the initiation of antiretroviral therapy: a prospective cardiovascular magnetic resonance study by Pieter-Paul S. Robbertse, Anton F. Doubell, Carl J. Lombard, Mohammed A. Talle, Philip G. Herbst

“…The HIV group was started on ART (tenofovir/lamivudine/dolutegravir) and prospectively evaluated 9 months later. …”
Get full text

Beyond clinical trials: Crosssectional associations of combination antiretroviral therapy with reports of multiple symptoms and nonadherence among adolescents in South Africa by H Natukunda, L Cluver, E Toska, V Musiime, A Yakubovich

“…Independent of covariates, stavudine (d4T)-containing cART regimens and the fixed-dose combination of tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV) were associated with more reports of multiple symptoms (adjusted odds ratio (aOR) 3.38; 95% CI 1.19 - 9.60 and aOR 2.67; 95% CI 1.21 - 5.88, respectively). …”
Get full text

Frequency of drug resistance and immune escape mutations in the hepatitis B virus genome detected in pregnant women in the Republic of Guinea by T.A.L. Balde, Yulia V. Ostankova, S. Boumbaly, Ekaterina V. Naidenova, Elena B. Zueva, Elena N. Serikova, Diana E. Valutite, Alexander N. Schemelev, Vladimir S. Davydenko, Elena V. Esaulenko, Areg A. Totolian

“…The presence of polymorphic variants not described as drug resistant has also been shown in positions associated with the development of drug resistance to tenofovir, lamivudine, telbivudine and entecavir (L80F, S202I, M204R). …”
Get full text

Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial by Iryna B. Zablotska, Christine Selvey, Rebecca Guy, Karen Price, Jo Holden, Heather-Marie Schmidt, Anna McNulty, David Smith, Fengyi Jin, Janaki Amin, David A. Cooper, Andrew E. Grulich, on behalf of the EPIC-NSW study group

“…Study participants receive once daily co-formulated tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) and are followed for up to 24 months. …”
Get full text

Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open... by Peng-Le Guo, Hao-Lan He, Xie-Jie Chen, Jin-Feng Chen, Xiao-Ting Chen, Yun Lan, Jian Wang, Pei-Shan Du, Huo-Lin Zhong, Hong Li, Cong Liu, Li-Ya Li, Feng-Yu Hu, Xiao-Ping Tang, Wei-Ping Cai, Ling-Hua Li

“…A randomized, controlled, open-label, non-inferiority trial (ALTERLL) was conducted to assess the efficacy, drug resistance, and safety of dual therapy with LPV/r plus 3TC (DT group), compared with the first-line triple-therapy regimen containing tenofovir (TDF), 3TC plus efavirenz (EFV) (TT group) in antiretroviral therapy (ART)-naïve HIV-1–infected adults in Guangdong, China. …”
Get full text

Are current guidelines adapted for patient eligibility to PrEP? A case report by Elise K. Van Obberghen, Delphine Viard, Alain Lafeuillade, Alexandre Civiletti, Fanny Rocher, Milou-Daniel Drici

“…PrEP therapy was then initiated with fixed association of emtricitabine-tenofovir disoproxil. One month later, HIV tests using two different assays were positive, despite perfect compliance reported by the patient and confirmed by plasma drug level. …”
Get full text

Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa. by Alana T Brennan, Lise Jamieson, Nigel J Crowther, Matthew P Fox, Jaya A George, Kaitlyn M Berry, Andrew Stokes, Mhairi Maskew, Ian Sanne, Lawrence Long, Naseem Cassim, Sydney Rosen

“…When assessing the choice of antiretroviral drug in first-line ART, patients initiated on nevirapine were at 27% increased risk of developing hypertension compared to those initiated on efavirenz, while patients who initiated on either zidovudine or stavudine had a 40% increased risk of developing hypertension compared to patients initiated on tenofovir. Patientswith poorer health status at ART initiation (i.e. …”
Get full text

Feasibility of vitamin D supplementation interventions to mitigate HIV pre-exposure prophylaxis-related bone mineral density loss: a cross-sectional survey by Wang S, Kortenaar JL, Hull MW, Arbess G, Owen JRM, Tan DHS

“…Michael&rsquo;s Hospital, Toronto, ON, Canada; 6Division of Infectious Diseases, University of Toronto, Toronto, ON, Canada Background: Daily tenofovir disoproxil fumarate (TDF)/emtricitabine as HIV pre-exposure prophylaxis (PrEP) causes subclinical decreases in bone mineral density (BMD). …”
Get full text